Arrowhead Pharmaceuticals
↗Pasadena, California, United States
Arrowhead Pharmaceuticals is a public biopharmaceutical company headquartered in Pasadena, California, that develops RNA interference (RNAi) therapeutics for treating intractable diseases by silencing disease-causing genes. The company leverages its proprietary TRiM™ (Targeted RNAi Molecule) platform, which utilizes RNA chemistries and delivery technologies with broad freedom to operate. After years of development, the company achieved its first FDA approval in November 2025 with REDEMPLO (plozasiran), a subcutaneous RNAi therapy for familial chylomicronemia syndrome (FCS), representing a significant commercial milestone for the RNAi field.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$829.4M-$1.09B (FY2025-FY2026 TTM)
Founded:1989
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$60M (pre-IPO only)
Investors:Silence Therapeutics
STOCK
Exchange:NASDAQ
Ticker:ARWR
Market Cap:$7.7B-$8.9B
PIPELINE
Stage:Commercial | Phase 3 | Phase 2 | Phase 1
Lead Drug Stage:FDA Approved (REDEMPLO)
Modalities:siRNA, RNA Interference, RNAi
Active Trials:8
Trial Phases:Phase 1: 2 | Phase 2: 3 | Phase 3: 2
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Novartis: $200M upfront for ARO-SNCA (Parkinson's), up to $2B in milestones (closed Oct 2025), GlaxoSmithKline: $120M upfront for NASH program (closed Jan 2022), up to $910M milestones, Takeda Pharmaceutical: $300M upfront for rare liver disease collaboration, Amgen: Exclusive worldwide license for olpasiran (cardiovascular), licensed Sept 2016, Sarepta Therapeutics: RNAi collaboration
COMPETITION
Position:Emerging Leader (first marketed RNAi product in competitive market with strong pipeline)
Competitors:Ionis Pharmaceuticals (antisense oligonucleotides), Alnylam Pharmaceuticals (RNAi leader, publicly traded), Dicerna Pharmaceuticals (Novo Nordisk subsidiary, RNAi), Eli Lilly (RNA therapeutics), Moderna Therapeutics (mRNA), ProQR Therapeutics (RNAi), Novartis (RNA programs), SanegeneBio +2 more
LEADERSHIP
Key Executives:
Christopher Anzalone - President, CEO & Chairman
Patrick O'Brien - Chief Operating Officer, General Counsel & Secretary
Tracie Oliver - Chief Commercial Officer
Aaron Tan - Head of Tax
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Arrowhead Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Arrowhead Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.